Novozymes A/S (NVZMY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Novozymes A/S (NVZMY) trades at $59.76 with AI Score 62/100 (Grade B+). Novozymes A/S is a global leader in biological solutions, focusing on enzymes and microorganisms. Market cap: $27.86B, Sector: Basic materials.
Last analyzed: Mar 17, 2026Analyst Coverage for NVZMY: NVZMY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NVZMY against Basic Materials peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NVZMY: 2/4 perspectives are bullish. Dominant signal: Izzy Englander bearish.
Novozymes A/S (NVZMY) Materials & Commodity Exposure
Novozymes A/S develops and produces industrial enzymes, microorganisms, and probiotics, serving diverse sectors like food, agriculture, and energy. With a global presence and a focus on sustainable solutions, the company addresses evolving industry needs through innovative biological technologies and applications.
What Is the Investment Thesis for NVZMY?
Novozymes A/S presents a compelling investment case based on its leading position in the enzyme and microbial technology market. The company's diverse product portfolio and global reach provide a stable revenue base, while its focus on innovation and sustainability positions it to capitalize on long-term growth trends in various industries. With a P/E ratio of 13.28 and a dividend yield of 1.83%, NVZMY offers a blend of value and income. Upcoming catalysts include expansion of bioenergy solutions and increasing demand for sustainable agricultural practices. However, investors should be aware of potential risks such as currency fluctuations and competition from other biotechnology companies.
Based on FMP financials and quantitative analysis
NVZMY Key Highlights
- Market capitalization of $25.63 billion reflects substantial investor confidence in Novozymes' market position.
- Profit margin of 8.4% demonstrates effective cost management and profitability in a competitive industry.
- Gross margin of 53.6% indicates strong pricing power and efficient production processes.
- Dividend yield of 1.83% provides a steady income stream for investors.
- Beta of 0.75 suggests lower volatility compared to the overall market, making it a relatively stable investment.
Who Are NVZMY's Competitors?
NVZMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AKZOY Akzo Nobel N.V. | $22.30 | +0.86% | $34.33B | 44 |
| AMSYF ArcelorMittal S.A. | $64.67 | +0.00% | $49.22B | 44 |
| EMSHF Ems-Chemie Holding AG | $877.91 | +0.00% | $20.53B | 45 |
| GVDBF Givaudan S.A. | $3950.00 | +0.35% | $36.46B | 50 |
| GVDNY Givaudan S.A. | $80.09 | +0.55% | $36.96B | 53 |
| COOSF Carbios SAS | $8.61 | +0.00% | $145.26M | 69 |
| LWLG Lightwave Logic, Inc. | $9.59 | -4.48% | $1.48B | 69 |
| HGRAF HydroGraph Clean Power Inc. | $5.00 | +0.81% | $1.70B | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NVZMY's Key Strengths?
- Leading market position in industrial enzymes.
- Diverse product portfolio across multiple industries.
- Strong research and development capabilities.
- Global presence and established distribution network.
What Are NVZMY's Weaknesses?
- Exposure to currency fluctuations.
- Dependence on commodity prices.
- Competition from larger chemical companies.
- Potential for regulatory changes affecting enzyme use.
What Could Drive NVZMY Stock Higher?
- Increasing demand for sustainable solutions in agriculture and food processing.
- Expansion of bioenergy solutions driven by government incentives and environmental regulations by Q4 2026.
- Strategic partnerships with key players in various industries to expand market reach.
- Launch of new enzyme products for specific applications in Q2 2027.
- Continued investment in research and development to drive innovation and product development.
What Are the Key Risks for NVZMY?
- Fluctuations in currency exchange rates affecting revenue and profitability.
- Competition from other biotechnology and chemical companies.
- Changes in government regulations affecting enzyme use and biofuel production.
- Economic downturns affecting industrial demand for enzymes and microbial solutions.
- Technological disruptions from competing technologies or alternative solutions.
What Are the Growth Opportunities for NVZMY?
- Expansion in Bioenergy Solutions: Novozymes has a significant opportunity to expand its bioenergy solutions, particularly in the production of advanced biofuels. As governments and industries seek to reduce carbon emissions and transition to renewable energy sources, the demand for enzymes that improve the efficiency of biofuel production is expected to increase. This market is projected to grow substantially by 2030, driven by supportive policies and technological advancements. Novozymes' expertise in enzyme technology and its partnerships with biofuel producers position it to capture a significant share of this growing market.
- Increasing Demand for Sustainable Agriculture: With growing concerns about the environmental impact of conventional agriculture, there is increasing demand for sustainable agricultural practices. Novozymes offers a range of biological solutions, including bioyield and biocontrol products, that can help farmers reduce their reliance on chemical fertilizers and pesticides. The market for these solutions is expanding rapidly, driven by consumer preferences for organic and sustainably produced food. Novozymes' focus on innovation in this area and its established distribution network provide a strong competitive advantage.
- Growth in Human Health and Protein Solutions: Novozymes is expanding its presence in the human health and protein solutions market, offering enzymes and microbial solutions for pharmaceutical applications, dietary supplements, and protein processing. This market is driven by increasing consumer awareness of health and wellness, as well as the growing demand for protein-rich foods. Novozymes' expertise in enzyme technology and its partnerships with pharmaceutical and food companies position it to capitalize on this growth opportunity. The company's rTrypsin product for cell culture is particularly promising.
- Penetration of Emerging Markets: Novozymes has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These markets are experiencing rapid economic growth and increasing demand for industrial enzymes and microbial solutions across various sectors. Novozymes' established global presence and its ability to tailor solutions to meet local needs provide a strong competitive advantage. The company's focus on building partnerships with local distributors and customers will be crucial for success in these markets.
- Innovation in Enzyme Discovery and Development: Novozymes' continued investment in research and development is crucial for its long-term growth. The company has a strong track record of discovering and developing novel enzymes and microbial solutions that address unmet needs in various industries. By focusing on innovation, Novozymes can maintain its competitive edge and capture new market opportunities. The company's expertise in enzyme engineering and its use of advanced technologies, such as genomics and proteomics, enable it to accelerate the discovery and development process.
What Opportunities Does NVZMY Have?
- Expanding bioenergy solutions.
- Increasing demand for sustainable agriculture.
- Growth in emerging markets.
- Innovation in enzyme discovery and development.
What Threats Does NVZMY Face?
- Economic downturns affecting industrial demand.
- Technological disruptions from competing technologies.
- Changes in government regulations.
- Increased competition from new entrants.
What Are NVZMY's Competitive Advantages?
- Proprietary enzyme technology and intellectual property.
- Extensive research and development capabilities.
- Global distribution network and established customer relationships.
- Strong brand reputation and market leadership in the enzyme industry.
What Does NVZMY Do?
Founded in 1925 and headquartered in Bagsvaerd, Denmark, Novozymes A/S has evolved into a global biotechnology leader specializing in enzyme and microbial technologies. The company's core business revolves around the discovery, development, and production of enzymes, microorganisms, and probiotics that enhance the performance and sustainability of various industrial processes and consumer products. Novozymes operates across a broad spectrum of industries, including food and beverage, where it offers solutions for baking, beverages, dairy, starch, and protein processing. In the household care sector, Novozymes provides enzymes for laundry detergents, dishwashing products, and cleaning agents. The company also has a significant presence in agriculture, offering solutions for crop production, animal health, and biocontrol. Furthermore, Novozymes develops bioenergy solutions for biofuel production and various other applications in textiles, pulp & paper, leather, and water & waste management. Novozymes' geographic reach spans Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America, allowing it to serve a diverse global customer base. The company differentiates itself through its extensive research and development capabilities, its commitment to sustainability, and its ability to tailor solutions to meet specific customer needs.
What Products and Services Does NVZMY Offer?
- Develops and produces industrial enzymes for various applications.
- Creates microorganisms and probiotics for use in different industries.
- Offers solutions for the food and beverage industry, including baking and dairy.
- Provides enzymes for household care products like laundry detergents.
- Develops agricultural solutions for crop production and animal health.
- Offers bioenergy solutions for biofuel production.
- Provides solutions for textile, pulp & paper, and leather industries.
- Develops water and waste management solutions.
How Does NVZMY Make Money?
- Develops and manufactures enzymes, microorganisms, and probiotics.
- Sells these biological solutions to various industries globally.
- Generates revenue through product sales and licensing agreements.
- Invests heavily in research and development to create new and improved products.
What Industry Does NVZMY Operate In?
Novozymes operates within the specialty chemicals industry, which is experiencing growth driven by increasing demand for sustainable and bio-based solutions. The global industrial enzymes market is projected to reach billions of dollars in the coming years, fueled by applications in food, beverages, animal feed, and biofuels. Novozymes competes with companies like AKZOY, AMSYF, EMSHF, GVDBF, and GVDNY, each vying for market share through innovation and strategic partnerships. Novozymes' focus on research and development and its broad product portfolio position it favorably in this competitive landscape.
Who Are NVZMY's Key Customers?
- Food and beverage manufacturers
- Household care product companies
- Agricultural businesses and farmers
- Biofuel producers
- Textile and leather manufacturers
NVZMY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Novozymes' future growth, indicating that key stakeholders believe in the company's potential.
- Community sentiment has turned positive, with many discussions highlighting Novozymes' innovative product pipeline and sustainability initiatives.
- Market perception is shifting favorably as Novozymes continues to strengthen its position in the biotechnological sector, capitalizing on the green transition.
- Analysts are noting that Novozymes' strong partnerships with major corporations enhance its market reach and credibility, boosting investor confidence.
Bear Case
- Concerns over supply chain disruptions have surfaced, potentially impacting Novozymes' ability to meet customer demand in the near term.
- Some community members express skepticism about the company's ability to maintain growth amidst increasing competition in the biotechnology space.
- Recent fluctuations in commodity prices may affect Novozymes' cost structure, leading to uncertainty in profitability moving forward.
- Investor sentiment remains cautious due to broader market volatility, with some viewing Novozymes as vulnerable to economic downturns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.14B | $202M | $0.43 |
| Q4 2025 | $997M | -$765M | -$1.62 |
| Q3 2025 | $1.06B | $137M | $0.30 |
| Q2 2025 | $137M | $18M | $0.04 |
Based on FMP financials and quantitative analysis
NVZMY Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· Feb 5, 2020
-
Stocks That Hit 52-Week Highs On Friday
· Jan 24, 2020
NVZMY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NVZMY.
Price Targets
Wall Street price target analysis for NVZMY.
NVZMY MoonshotScore
What does this score mean?
The MoonshotScore rates NVZMY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ester Baiget
CEO
Ester Baiget is the CEO of Novozymes A/S. She brings extensive experience in the chemical and materials industries, having held leadership positions at Dow Chemical and DuPont. Her background includes a strong focus on innovation, sustainability, and business development. Baiget's expertise spans various areas, including strategy, operations, and commercialization. She holds advanced degrees in chemical engineering and business administration.
Track Record: Since becoming CEO, Ester Baiget has focused on driving innovation and expanding Novozymes' presence in key growth markets. She has overseen the launch of new products and solutions, as well as strategic partnerships and acquisitions. Under her leadership, Novozymes has strengthened its commitment to sustainability and its focus on creating value for customers and shareholders.
Novozymes A/S ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. NVZMY is an ADR representing shares of Novozymes A/S, a Danish company. This allows U.S. investors to easily invest in Novozymes without dealing with foreign exchanges or currencies. The ADR is denominated in U.S. dollars and trades during U.S. market hours.
- Home Market Ticker: Nasdaq Copenhagen, Denmark
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: NVZM
NVZMY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited or no financial disclosure and may not meet minimum listing requirements. This is in contrast to companies listed on major exchanges like the NYSE or NASDAQ, which have stringent listing standards and reporting obligations. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher degree of regulatory risk.
- Increased risk of delisting or suspension of trading.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Research the company's management team and track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Established operating history and market presence.
- Positive customer reviews and testimonials.
- Partnerships with reputable companies.
- Independent audits of financial statements.
- Active investor relations and communication.
Common Questions About NVZMY (Basic Materials)
What does Novozymes A/S do?
Novozymes A/S is a global biotechnology company specializing in the production and sale of industrial enzymes, microorganisms, and probiotics. These biological solutions are used in a wide range of industries, including food and beverage, household care, agriculture, and bioenergy. The company's products enhance the efficiency and sustainability of various industrial processes, contributing to resource optimization and environmental protection. Novozymes' market position is built on its extensive research and development capabilities, its diverse product portfolio, and its global presence.
What do analysts say about NVZMY stock?
Analyst consensus for NVZMY stock is mixed, reflecting the company's diverse business segments and exposure to various macroeconomic factors. Key valuation metrics, such as the P/E ratio and dividend yield, are closely monitored. Growth considerations include the company's ability to capitalize on increasing demand for sustainable solutions and its success in launching new products. Analysts also consider potential risks, such as currency fluctuations and competition. However, there is no universal agreement on the stock's future performance.
What are the main risks for NVZMY?
The main risks for Novozymes A/S include currency fluctuations, as the company operates globally and is exposed to exchange rate volatility. Competition from other biotechnology and chemical companies also poses a risk, as does the potential for changes in government regulations affecting enzyme use and biofuel production. Economic downturns could reduce industrial demand for the company's products, and technological disruptions from competing technologies could also impact its market position. These risks should be carefully considered by investors.
What are the key factors to evaluate for NVZMY?
Novozymes A/S (NVZMY) holds an AI score of 62/100 (moderate). Not financial advice.
How frequently does NVZMY data refresh on this page?
NVZMY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NVZMY's recent stock price performance?
Novozymes A/S (NVZMY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading market position in industrial enzymes. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NVZMY overvalued or undervalued right now?
Valuing Novozymes A/S (NVZMY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NVZMY?
Before investing in Novozymes A/S (NVZMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data and market information are based on available sources and may be subject to change.
- This analysis is for informational purposes only and does not constitute investment advice.
- OTC market data may be limited and less reliable than data from major exchanges.